Rachel G Greenberg1, Sreepriya Gayam2, Destiny Savage2, Andrew Tong2, Daniel Gorham2, Ari Sholomon2, Reese H Clark3, Daniel K Benjamin4, Matthew Laughon5, P Brian Smith6. 1. Department of Pediatrics, Duke University School of Medicine, Durham, NC; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC. Electronic address: rachel.greenberg@duke.edu. 2. Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC. 3. Pediatrix-Obstetrix Center for Research and Education, Sunrise, FL. 4. Clemson University, Clemson, SC. 5. Department of Pediatrics, The University of North Carolina-Chapel Hill, Chapel Hill, NC. 6. Department of Pediatrics, Duke University School of Medicine, Durham, NC; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
Abstract
OBJECTIVE: To evaluate the association between furosemide exposure and risk of bronchopulmonary dysplasia (BPD). STUDY DESIGN: This retrospective cohort study included infants (2004-2015) born at 23-29 weeks gestational age and 501-1249 g birth weight. We compared the demographic and clinical characteristics of infants exposed and not exposed to furosemide between postnatal day 7 and 36 weeks postmenstrual age. We examined the association between furosemide exposure and 2 outcomes: BPD and BPD or death. We performed multivariable probit regression models that included demographic and clinical variables in addition to 2 instrumental variables: furosemide exposure by discharge year, and furosemide exposure by site. RESULTS: Of 37 693 included infants, 19 235 (51%) were exposed to furosemide; these infants were more premature and had higher respiratory support. Of 33 760 infants who survived to BPD evaluation, 15 954 (47%) had BPD. An increase in the proportion of furosemide exposure days by 10 percentage points was associated with a decrease in both the incidence of BPD (4.6 percentage points; P = .001), and BPD or death (3.7 percentage points; P = .01). CONCLUSIONS: More days of furosemide exposure between postnatal day 7 and 36 weeks was associated with decreased risk of BPD and a combined outcome of BPD or death.
OBJECTIVE: To evaluate the association between furosemide exposure and risk of bronchopulmonary dysplasia (BPD). STUDY DESIGN: This retrospective cohort study included infants (2004-2015) born at 23-29 weeks gestational age and 501-1249 g birth weight. We compared the demographic and clinical characteristics of infants exposed and not exposed to furosemide between postnatal day 7 and 36 weeks postmenstrual age. We examined the association between furosemide exposure and 2 outcomes: BPD and BPD or death. We performed multivariable probit regression models that included demographic and clinical variables in addition to 2 instrumental variables: furosemide exposure by discharge year, and furosemide exposure by site. RESULTS: Of 37 693 included infants, 19 235 (51%) were exposed to furosemide; these infants were more premature and had higher respiratory support. Of 33 760 infants who survived to BPD evaluation, 15 954 (47%) had BPD. An increase in the proportion of furosemide exposure days by 10 percentage points was associated with a decrease in both the incidence of BPD (4.6 percentage points; P = .001), and BPD or death (3.7 percentage points; P = .01). CONCLUSIONS: More days of furosemide exposure between postnatal day 7 and 36 weeks was associated with decreased risk of BPD and a combined outcome of BPD or death.
Authors: B R Vohr; L L Wright; A M Dusick; L Mele; J Verter; J J Steichen; N P Simon; D C Wilson; S Broyles; C R Bauer; V Delaney-Black; K A Yolton; B E Fleisher; L A Papile; M D Kaplan Journal: Pediatrics Date: 2000-06 Impact factor: 7.124
Authors: Edwin P Martens; Wiebe R Pestman; Anthonius de Boer; Svetlana V Belitser; Olaf H Klungel Journal: Epidemiology Date: 2006-05 Impact factor: 4.822
Authors: Thérèse A Stukel; Elliott S Fisher; David E Wennberg; David A Alter; Daniel J Gottlieb; Marian J Vermeulen Journal: JAMA Date: 2007-01-17 Impact factor: 56.272
Authors: Eleri W Adams; Michael C Harrison; Serena J Counsell; Joanna M Allsop; Nigel L Kennea; Joseph V Hajnal; Anna S Thornton; Philip Duggan; A David Edwards Journal: J Pediatr Date: 2004-10 Impact factor: 4.406
Authors: Elizabeth J Thompson; Daniel K Benjamin; Rachel G Greenberg; Karan R Kumar; Kanecia O Zimmerman; Matthew Laughon; Reese H Clark; P Brian Smith; Christoph P Hornik Journal: Neonatology Date: 2020-10-07 Impact factor: 4.035
Authors: Nicolas A Bamat; Elizabeth J Thompson; Rachel G Greenberg; Scott A Lorch; Athena F Zuppa; Eric C Eichenwald; Veeral N Tolia; Reese H Clark; P Brian Smith; Christoph P Hornik; Jason E Lang; Matthew M Laughon Journal: J Perinatol Date: 2022-01-24 Impact factor: 3.225
Authors: Nicolas A Bamat; Timothy D Nelin; Eric C Eichenwald; Haresh Kirpalani; Matthew M Laughon; Wesley M Jackson; Erik A Jensen; Kathleen A Gibbs; Scott A Lorch Journal: J Pediatr Date: 2020-11-03 Impact factor: 4.406